Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Oct 11 2022 | scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure Industry News Industry Read More Oct 1 2022 | HFSA Collaborates with the Foundation for the National Institutes of Health (FNIH) and the National Heart, Lung, and Blood Institute (NHLBI) on the launch of the new Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program Practice News In The News Press Release Read More Sep 25 2022 | HFSA President's Update: September 2022 HFSA News President's Updates Read More Sep 19 2022 | Protecting Your Heart and Your Loved One’s Hearts with Genetic Testing Patient News Heart Failure Awareness 365 Patient Resource Read More Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Oct 11 2022 | scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure Industry News Industry Read More
Oct 1 2022 | HFSA Collaborates with the Foundation for the National Institutes of Health (FNIH) and the National Heart, Lung, and Blood Institute (NHLBI) on the launch of the new Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program Practice News In The News Press Release Read More
Sep 19 2022 | Protecting Your Heart and Your Loved One’s Hearts with Genetic Testing Patient News Heart Failure Awareness 365 Patient Resource Read More
Sep 8 2022 | FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
